BioCentury | Apr 22, 2020
Finance

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

...Co. Ltd. raised RMB100 million ($14.1 million) in a pre-C round to advance its pipeline. Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

...DARPin) that antagonizes VEGF-A, in Phase III testing for AMD and DME. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Feb 5, 2019
Distillery Therapeutics

Neurology

...Next steps could include testing P2RX7 inhibitors in other models of autism. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

...inhibitors in the models. The generic probenecid is marketed to treat gout. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Jan 23, 2018
Distillery Therapeutics

Transplant

...undisclosed inhibitors of P2RX7 and its downstream pathway in transplant rejection patients. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 24, 2017
Distillery Therapeutics

Endocrine / Metabolic

...Next steps include clinical testing of P2X7 inhibitors in diabetic nephropathy patients. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Jan 3, 2017
Distillery Therapeutics

Inflammation; dermatology; renal

...Next steps could include testing the nanobodies in additional models of inflammation. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

...the tricyclic antidepressant (TCA) Tofranil imipramine hydrochloride to treat depression and incontinence. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Interleukin-1 (IL-1) β; IL-1 receptor; purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

...inhibitors of P2RX7 and IL-1β/IL-1 receptor signaling in additional models of AMD. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 7, 2012
Finance

Highlights of weekly biotech stock moves

...Flow Evotec AG (Xetra:EVT) was off €0.05 to €2.49 last week after granting Zhejiang Jinhua Conba...
...$79.4 million) in milestones, plus tiered, double-digit royalties. Zhejiang Jinhua is a subsidiary of the Conba...
Items per page:
1 - 10 of 13
BioCentury | Apr 22, 2020
Finance

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

...Co. Ltd. raised RMB100 million ($14.1 million) in a pre-C round to advance its pipeline. Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

...DARPin) that antagonizes VEGF-A, in Phase III testing for AMD and DME. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Feb 5, 2019
Distillery Therapeutics

Neurology

...Next steps could include testing P2RX7 inhibitors in other models of autism. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

...inhibitors in the models. The generic probenecid is marketed to treat gout. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Jan 23, 2018
Distillery Therapeutics

Transplant

...undisclosed inhibitors of P2RX7 and its downstream pathway in transplant rejection patients. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 24, 2017
Distillery Therapeutics

Endocrine / Metabolic

...Next steps include clinical testing of P2X7 inhibitors in diabetic nephropathy patients. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Jan 3, 2017
Distillery Therapeutics

Inflammation; dermatology; renal

...Next steps could include testing the nanobodies in additional models of inflammation. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

...the tricyclic antidepressant (TCA) Tofranil imipramine hydrochloride to treat depression and incontinence. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Interleukin-1 (IL-1) β; IL-1 receptor; purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

...inhibitors of P2RX7 and IL-1β/IL-1 receptor signaling in additional models of AMD. Evotec AG and Zhejiang Conba Pharmaceutical Co. Ltd....
BioCentury | May 7, 2012
Finance

Highlights of weekly biotech stock moves

...Flow Evotec AG (Xetra:EVT) was off €0.05 to €2.49 last week after granting Zhejiang Jinhua Conba...
...$79.4 million) in milestones, plus tiered, double-digit royalties. Zhejiang Jinhua is a subsidiary of the Conba...
Items per page:
1 - 10 of 13